American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with a rationally selected treatment. The aim is to examine the effects of targeted therapies (drugs like Gleevec, Sutent, Stivarga, etc.) in patients that have failed standard therapies. ASCO is in discussion with several pharmaceutical companies to involve their therapies.
ASCO would like to offer the treatments at no cost to the patient (but this is still under discussion with participating entities). This might allow patients without access to off-label treatments or clinical trials access to additional treatments at little or no cost to the patient. In addition, the clinical data would be gathered and analyzed thus contributing to knowledge about the treatment and disease.
